CNS Pharmaceuticals Inc. (CNSP) announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme or GBM, one of the most aggressive types of brain cancer.
The company said it continues to drive further patient enrollment with 9 clinical trial sites initiated to-date, and an additional 60 sites selected across the U.S., Italy, France, Spain, and Switzerland expected to initiate imminently.
The FDA recently granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with the FDA to expedite the development and review process.
Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier currently being evaluated in a global potentially pivotal study evaluating its efficacy and safety. Approximately 243 patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive Berubicin or lomustine for the evaluation of Overall Survival, the primary endpoint of the study.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.